Segmed Deepens Verily Collaboration to Expand Access to Biomedical Data Platform

According to a recent LinkedIn post from Segmed, the company is collaborating with Verily, part of Alphabet Inc., to expand access to Verily’s Pre Exchange and Workbench via a new free self-serve Standard tier. The post highlights that this tier is intended to broaden secure and compliant access to biomedical data infrastructure for the research community.

The company’s LinkedIn post suggests that Segmed is providing longitudinal, real-world imaging data linked to structured clinical information to support precision health, AI development, and translational research. It also emphasizes a focus on research-ready, responsibly de-identified datasets designed to meet standards for rigorous scientific and regulatory-grade work.

For investors, the collaboration with Verily may indicate deeper integration into a larger health-data ecosystem associated with Alphabet, potentially enhancing Segmed’s visibility and distribution channels. Access via a free standard tier could expand the user base and data usage, which may support long-term monetization opportunities through higher-value tiers or specialized datasets.

The emphasis on regulatory-grade, de-identified real-world imaging data positions Segmed within a segment of the health data market that is increasingly important for AI model training and evidence generation. If adoption within the Verily ecosystem grows, this could strengthen Segmed’s competitive position in precision health and biomedical data services, though the post does not provide financial terms or revenue implications.